SMAD4 antibody (full length)

Catalog No. ABIN7879056

The Mouse Monoclonal anti-SMAD4 antibody is suitable to detect SMAD4 in samples from Human. It has been validated for IHC (p).

Quick Overview for SMAD4 antibody (full length) (ABIN7879056)

Target: SMAD4 (SMAD Family Member 4 (SMAD4))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This SMAD4 antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: SPM448

Product Details anti-SMAD4 Antibody

Binding Specificity: full length

Purpose: SMAD4 Antibody

Purification: Protein G affinity chromatography

Immunogen: Recombinant full-length human protein was used as the immunogen for the SMAD4 antibody.

Isotype: IgG2a, kappa

Application Details

Application Notes: Optimal dilution of the SMAD4 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.2 mg/mL

Buffer: 0.2 mg/mL in 1X PBS with 0.1 mg/mL BSA (US sourced) and 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store the SMAD4 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Target Details for SMAD4

Target: SMAD4 (SMAD Family Member 4 (SMAD4))

Alternative Name: SMAD4

Background: Signaling from the ligand-activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF- family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. SMAD4 is absent in approximately 80 % of pancreatic adenocarcinoma, but rarely in endometrial, colorectal, ovarian, lung, breast adenocarcinomas, and malignant melanom. SMAD4 is an important marker for confirming a diagnosis of pancreatic adenocarcinoma. Patients with pancreatic adenocarcinomas with SMAD4 protein expression had significantly longer survival than SMAD4 negative patients.

UniProt: Q13485

Pathways: Cell Division Cycle, Chromatin Binding, Autophagy